Cellromax Science Co., Ltd. Logo

Cellromax Science Co., Ltd.

Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.

471820 | KO

Overview

Corporate Details

ISIN(s):
KR7471820001
LEI:
Country:
South Korea
Address:
경기도 용인시 기흥구 구성로 357 D동 710호 (청덕동, 용인테크노밸리), 용인시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cellromax Science Co., Ltd. is a KOSDAQ-listed company specializing in the development, manufacturing, and distribution of health-oriented products. Its primary business divisions include health functional foods, derma-cosmetics, and over-the-counter (OTC) pharmaceuticals. The company focuses on creating differentiated products through dedicated research, using carefully selected natural-origin raw materials and optimal formulation science. Key product features include specialized prescriptions and user-friendly formulation technology. Cellromax Science distributes its products through pharmacies and direct-to-consumer online channels. The company was formerly known as Pharmacist & Health Co., Ltd. and rebranded in 2021.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정 (분기배당)
Korean 8.1 KB
2025-09-12 00:00
Notice of Dividend Amount
중간(분기)배당을위한주주명부폐쇄(기준일)결정
Korean 5.5 KB
2025-09-01 00:00
Share Issue/Capital Change
감자완료
Korean 8.9 KB
2025-08-27 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-08-13 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(감자결정)
Korean 22.5 KB
2025-08-12 00:00
Share Issue/Capital Change
[기재정정]전환청구권행사 (제1회차)
Korean 11.8 KB
2025-07-23 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 5.6 KB
2025-07-22 00:00
Share Issue/Capital Change
전환청구권행사 (제1회차)
Korean 8.7 KB
2025-07-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-07-10 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-07-09 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정 (분기배당)
Korean 8.8 KB
2025-07-09 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약체결결정)
Korean 35.5 KB
2025-07-08 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 58.7 KB
2025-07-07 00:00
Regulatory News Service
신탁계약해지결과보고서
Korean 35.1 KB
2025-06-13 00:00
Notice of Dividend Amount
수시공시의무관련사항(공정공시) (주주가치 제고를 위한 주주환원계획 수립)
Korean 8.8 KB

Automate Your Workflow. Get a real-time feed of all Cellromax Science Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cellromax Science Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cellromax Science Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.